title: Something rotten in the state of clinical and economic evaluations?
authors.forename: N
authors.initials: N
authors.lastname: Freemantle
authors.forename: A
authors.initials: A
authors.lastname: Maynard
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000191:economics / Q000627:therapeutic use; D015982:Bias; D002986:Clinical Trials as Topic / Q000191:economics* / Q000706:statistics & numerical data; D003362:Cost-Benefit Analysis; D003866:Depressive Disorder / Q000188:drug therapy / Q000191:economics; D004358:Drug Therapy / Q000191:economics* / Q000706:statistics & numerical data; D017048:Health Care Costs / Q000639:trends*; D006801:Humans; D007099:Imipramine / Q000191:economics / Q000627:therapeutic use; D017374:Paroxetine / Q000191:economics / Q000627:therapeutic use; D015871:Scientific Misconduct; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D017374:Paroxetine; D007099:Imipramine